Most PDAC tumors are driven by aberrant KRAS activity (5), and a line of evidence suggests that oncogenic KRAS signaling enhances glycolysis (6) in cancer cells by increasing the expression of glycolytic enzymes, such as lactate dehydrogenase A (LDHA) (7). This evidence concerns the gene KRAS and cancer.